Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY3283142
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BAY3283142 is an investigational small molecule drug developed by Bayer for the treatment of chronic kidney disease (CKD) and related cardiovascular conditions. It acts as a soluble guanylate cyclase (sGC) activator, stimulating the sGC enzyme to increase levels of cyclic guanosine monophosphate (cGMP), which relaxes blood vessels and is thought to have beneficial effects in CKD. The drug is currently in Phase II clinical trials for CKD, with additional studies evaluating its safety in patients with mild to moderate hypertension. There are also indications that it may be under development for nonproliferative diabetic retinopathy (NPDR). By targeting the nitric oxide-sGC-cGMP pathway, BAY3283142 aims to address unmet medical needs in renal and cardiovascular diseases[1][3][5][6][7][8].
- Other names
- Nurandociguatum
02
Targets
sGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on BAY3283142.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAY3283142.